Cosmo Pharmaceuticals N.V./€COPN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.

Ticker

€COPN
Sector
Health

Primary listing

XGAT

Employees

332

Headquarters

Dublin, Ireland
Website
www.cosmopharma.com

COPN Metrics

BasicAdvanced
€1.1B
19.63
€3.67
-
€2.05
2.85%

Bulls say / Bears say

Cosmo achieved record full-year 2024 revenue of €266.8 million, a 188% year-over-year increase at the high end of guidance, fueled by €190.2 million in GI Genius™ and Winlevi® milestone income. (Cosmo Pharma)
Recurring revenues in H1 2025 saw robust growth with GI Genius™ up by 128% and Winlevi® up by 23%, supporting a €4.5 million increase to full-year EBITDA guidance. (Cosmo Pharma)
Cosmo completed Phase III enrollment for clascoterone solution in androgenetic alopecia—the first new mechanism of action in 30 years. Topline Phase III results expected in early H2 2025 boost the pipeline's mid-term outlook. (Cosmo Pharma)
Cosmo's dependence on milestone-driven revenues leads to sharp fluctuations, as seen with project-based revenues falling to €9.8 million in H1 2025 from €93.9 million in H1 2024, highlighting the unpredictability of its topline performance. (Cosmo Pharma)
Without significant milestone payments, Cosmo posted an operating loss of €1.4 million in H1 2025 compared to a €78.7 million profit in the same period the previous year, indicating ongoing pressure on its core profitability. (Cosmo Pharma)
The guidance for full-year 2025 revenues at €102–107 million marks a significant drop from the €266.8 million reported in 2024, signaling challenges in maintaining growth without major project-based milestones. (Cosmo Pharma)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €COPN

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs